ArriVent BioPharma, Inc.
AVBP
$20.11
$0.231.16%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 44.90% | 48.99% | 57.68% | 77.17% | 72.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.67% | 20.84% | 26.44% | 51.37% | 51.33% |
| Operating Income | -25.67% | -20.84% | -26.44% | -51.37% | -51.33% |
| Income Before Tax | -82.93% | -70.91% | -16.09% | -38.35% | -33.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -82.93% | -70.91% | -16.09% | -38.35% | -33.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -82.93% | -70.91% | -16.09% | -38.35% | -33.85% |
| EBIT | -25.67% | -20.84% | -26.44% | -51.37% | -51.33% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 72.61% | 84.78% | 92.34% | 71.21% | 60.98% |
| Normalized Basic EPS | 80.65% | 89.53% | 92.34% | 71.21% | 60.98% |
| EPS Diluted | 72.61% | 84.78% | 92.34% | 71.21% | 60.98% |
| Normalized Diluted EPS | 80.65% | 89.53% | 92.34% | 71.21% | 60.98% |
| Average Basic Shares Outstanding | 113.25% | 316.14% | 1,361.71% | 1,222.06% | 993.08% |
| Average Diluted Shares Outstanding | 113.25% | 316.14% | 1,361.71% | 1,222.06% | 993.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |